Athira Pharma Inc. set terms Monday for its initial public offering, in which the the biopharmaceutical company focused on developing treatment for neurological diseases, including Alzheimer's disease, can raise up to $170 million and be valued at up to about $489.5 million. The company is offering 10 million shares in the IPO, which is expected to price at $15 to $17. Athira's stock is expected to trade on the Nasdaq under the ticker symbol "ATHA." The company will have 28.8 million shares outstanding after the IPO. Goldman Sachs, Jefferies and Stifel Nicolaus and JMP are the lead underwriters.